Douglas Lyles

Cooley advised the underwriters of StubHub Holdings, a global secondary ticketing marketplace for live events, in connection with StubHub’s $800 million initial public offering (IPO).

Cooley advised Clubessential Holdings, a global provider of software as a service and embedded payments solutions for membership-based organizations, backed by Battery Ventures and Silver Lake, on its definitive agreement to merge with Xplor Technologies, a platform providing software and embedded payments solutions to businesses in everyday life verticals, such as childcare and education, fitness and wellbeing, field services, and personal services.

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.

Cooley advised Advanced Instruments, a subsidiary of Patricia Industries and a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, on intellectual property and licensing aspects in connection with its definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients and the development of biotechnology therapeutics.

Cooley successfully lifted a Hatch-Waxman injunction for Liquidia Technologies, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products, enabling Liquidia to launch its new drug, Yutrepia.